Quick Answer
Vicapsys Life Sciences, Inc. reported Stockholders Equity of -$1.93 million for the year ending 2023.
- Vicapsys Life Sciences, Inc. showed a decrease of -102.9% in Stockholders Equity from 2022 to 2023.
- This data is from Vicapsys Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on October 21, 2024.
- XBRL data for this metric is available from 2018 to 2023 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$696.3 thousand | Q2 2019: $480.8 thousand | Q3 2019: $546.2 thousand | Q1 2020: -$62.5 thousand | Q2 2020: -$294.1 thousand | Q3 2020: -$369.6 thousand | Q1 2021: -$397.8 thousand | Q2 2021: -$258.8 thousand | Q3 2021: -$193.9 thousand | Q1 2022: -$287.6 thousand | Q2 2022: -$466.6 thousand | Q3 2022: -$520.3 thousand | Q4 2022: -$950.8 thousand | Q1 2023: -$1.14 million | Q2 2023: -$1.09 million | Q3 2023: -$1.33 million | Q4 2023: -$1.93 million | Q1 2024: -$2.26 million | Q2 2024: -$2.45 million | Q3 2024: -$2.65 million.
- Over the full 6 years of available data (2018 to 2023), Vicapsys Life Sciences, Inc.'s Stockholders Equity has declined by 660.3%.
- Historical annual values: Fiscal year 2023: -$1.93 million | Fiscal year 2022: -$950.8 thousand | Fiscal year 2021: -$121.7 thousand | Fiscal year 2020: -$449.1 thousand | Fiscal year 2019: $302.0 thousand | Fiscal year 2018: -$253.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: